Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Youth Power Action Feasibility Study of Online Support Group Intervention Among Adolescents Living With HIV in Nigeria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03076996
Recruitment Status : Completed
First Posted : March 10, 2017
Results First Posted : February 18, 2019
Last Update Posted : March 5, 2019
Sponsor:
Information provided by (Responsible Party):
FHI 360

Brief Summary:
This study will examine the feasibility and acceptability of an intervention designed to improve retention in HIV care services and improve anti-retroviral therapy (ART) adherence among adolescents ages 15-19 years living with HIV enrolled in ART services.

Condition or disease Intervention/treatment Phase
HIV/AIDS Adolescent Behavior Medication Adherence Health Behavior Behavioral: Online support group Not Applicable

Detailed Description:

Study aim is to examine the feasibility and acceptability of an intervention designed to improve retention in HIV care services and improve anti-retroviral therapy (ART) adherence among adolescents ages 15-19 years living with HIV enrolled in ART services.

A single group, pre/posttest design including structured questionnaires with adolescents living with HIV. Additionally, we will abstract clinical data from the medical record system. We will also conduct in-depth interviews with a subset of participants, as well as health care staff who are engaged in the intervention, at endline.

The objectives of this study are:

  1. To examine the feasibility of implementing a mobile/electronic health (m/eHealth) intervention designed to improve retention in HIV care services and ART adherence among ALHIV ages 15-19 years through an online support group (using Facebook).
  2. To assess acceptability of and engagement in the intervention by the target audience to inform improvements to the intervention.
  3. To gather preliminary data on the psycho-social and health-related outcomes that the intervention is designed to affect to inform an outcome evaluation study that will be conducted following the conclusion of the feasibility study.
  4. To collect information on recruitment, informed consent and data collection processes to inform the outcome evaluation study of the current intervention that will be conducted once findings from this feasibility study are incorporated into the intervention design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single group pre/post design
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Youth Power Action Feasibility Study of Online Support Group Intervention Among Adolescents Living With HIV in Nigeria
Actual Study Start Date : June 1, 2017
Actual Primary Completion Date : January 15, 2018
Actual Study Completion Date : January 15, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Online support group
Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
Behavioral: Online support group

Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.

The m/eHealth intervention components include:

  • Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis
  • Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis
  • Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed




Primary Outcome Measures :
  1. Percentage of Active Members Who Have at Least One Post in Group Chat Session. [ Time Frame: 3 months ]
    Participants level of engagement in support group activities informs on the feasibility of intervention, measured by percentage of active members who have at least one post in group chat session.


Secondary Outcome Measures :
  1. Acceptability Score [ Time Frame: 3 months ]
    Acceptability score: A set of ten items asking if participants agreed=1 or disagreed=0 with statements on acceptability. Score represents a sum of the 10 items with a range of 0 to 10, and a greater number indicating agreement with more acceptability items.

  2. Adherence to ART as Measured by the AACTG Adherence Assessment [ Time Frame: 3 months ]
    Proportion of participants who report not having missed any ART doses in past 3 days.

  3. Adherence to Follow-up Visit Within 1 Month of Scheduled Date [ Time Frame: 3 months ]
    Retention in HIV services will be measured using data abstracted from the medical record system on date of visits between enrollment and the endline of this study. To be considered retained in HIV services, an individual must, at 3 months after enrollment, have attended his/her most recently scheduled clinical follow-up visit within 1 month of the date when it was scheduled to take place.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • HIV positive and currently on ART for at least 6 months
  • Age 15 to 19 years
  • Can demonstrate basic literacy necessary to participate in online chats

Exclusion Criteria:

  • Not planning to remain in the study area (within Akwa Ibom State) for the duration of the study (approximately 6 months)
  • Currently enrolled in an in-person support group
  • Currently enrolled in another research study related to HIV service retention or ART adherence
  • Critically or severely ill requiring hospitalization or such that the individual is unable to provide informed consent at the time of study recruitment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03076996


Locations
Layout table for location information
Nigeria
SIDHAS-supported facilities
Uyo, Always Ibom, Nigeria
Sponsors and Collaborators
FHI 360
Investigators
Layout table for investigator information
Principal Investigator: Lisa S Dulli, PhD FHI 360
  Study Documents (Full-Text)

Documents provided by FHI 360:
Study Protocol  [PDF] August 2, 2017
Statistical Analysis Plan  [PDF] August 29, 2017


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: FHI 360
ClinicalTrials.gov Identifier: NCT03076996     History of Changes
Other Study ID Numbers: 930307
First Posted: March 10, 2017    Key Record Dates
Results First Posted: February 18, 2019
Last Update Posted: March 5, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No